Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Core Binding Factors"" wg kryterium: Temat


Tytuł:
High IL2RA/CD25 expression is a prognostic stem cell biomarker for pediatric acute myeloid leukemia without a core-binding factor.
Autorzy:
Aoki T; Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba, Japan.
Shiba N; Department of Pediatrics, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Tsujimoto S; Department of Pediatrics, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Yamato G; Department of Pediatrics, Gunma University Graduate School of Medicine, Maebashi, Japan.
Hara Y; Department of Pediatrics, Gunma University Graduate School of Medicine, Maebashi, Japan.
Kato S; Department of Pediatrics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Yoshida K; Division of Cancer Evolution, National Cancer Center Research Institute, Tokyo, Japan.
Ogawa S; Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.; Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto, Japan.; Department of Medicine, Center for Hematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden.
Hayashi Y; Institute of Physiology and Medicine, Jobu University, Takasaki, Japan.
Iwamoto S; Department of Pediatrics, Mie University, Tsu, Japan.
Taki T; Department of Medical Technology, Kyorin University Faculty of Health Sciences, Mitaka, Japan.
Shimada A; Department of Pediatrics, Jichi Medical University, Shimotsuke, Japan.
Iijima-Yamashita Y; Clinical Research Center, NHO Nagoya Medical Center, Nagoya, Japan.
Horibe K; Clinical Research Center, NHO Nagoya Medical Center, Nagoya, Japan.
Tawa A; Higashiosaka Aramoto Heiwa Clinic, Higashiosaka, Japan.
Taga T; Department of Pediatrics, Shiga University of Medical Science, Shiga, Japan.
Adachi S; Department of Human Health Science, Kyoto University, Kyoto, Japan.
Tomizawa D; Division of Leukemia and Lymphoma, Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.
Pokaż więcej
Źródło:
Pediatric blood & cancer [Pediatr Blood Cancer] 2024 Feb; Vol. 71 (2), pp. e30803. Date of Electronic Publication: 2023 Dec 06.
Typ publikacji:
Journal Article
MeSH Terms:
Core Binding Factors*
Leukemia, Myeloid, Acute*/therapy
Leukemia, Myeloid, Acute*/drug therapy
Child ; Humans ; Prognosis ; Neoplastic Stem Cells ; Biomarkers/metabolism ; Interleukin-2 Receptor alpha Subunit
Czasopismo naukowe
Tytuł:
Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective study.
Autorzy:
Gabellier L; Département d'Hématologie Clinique, CHU Montpellier, Université Montpellier-Nîmes, 80, Avenue Augustin Fliche, 34090, Montpellier, France. .
Peterlin P; Département d'Hématologie Clinique, CHU Nantes, Université de Nantes, Nantes, France.
Thepot S; Département d'Hématologie Clinique, CHU Angers, Université d'Angers, Angers, France.
Hicheri Y; Département d'Hématologie Clinique, Institut Paoli-Calmettes, Marseille, France.
Paul F; Département d'Hématologie Clinique, CHU Montpellier, Université Montpellier-Nîmes, 80, Avenue Augustin Fliche, 34090, Montpellier, France.
Gallego-Hernanz MP; Département d'Hématologie Clinique, CHU Poitiers, Université de Poitiers, Poitiers, France.
Bertoli S; Service d'Hématologie Clinique, CHU Toulouse, Institut Universitaire du Cancer de Toulouse - Oncopôle, Université Toulouse III - Paul Sabatier, Toulouse, France.
Turlure P; Département d'Hématologie Clinique, CHU Limoges, Université de Limoges, Limoges, France.
Pigneux A; Département d'Hématologie Clinique, CHU Bordeaux, Université de Bordeaux, Bordeaux, France.
Guieze R; Département d'Hématologie Clinique, CHU Clermont-Ferrand, Université de Clermont-Ferrand, Clermont-Ferrand, France.
Ochmann M; Département d'Hématologie Clinique, Orléans, Orléans, CH, France.
Malfuson JV; Département d'Hématologie Clinique, Hôpital d'instruction Des Armées, Percy, France.
Cluzeau T; Département d'Hématologie Clinique, CHU Nice, Université de Nice, Nice, France.
Thomas X; Département d'Hématologie Clinique, Hospices Civils de Lyon, CHU Lyon, Université de Lyon, Lyon, France.
Tavernier E; Département d'Hématologie Clinique, Institut de Cancérologie Lucien Neuwirth, Université de Saint-Etienne, Saint-Etienne, France.
Jourdan E; Département d'Hématologie Clinique, CHU Nîmes, Université de Montpellier-Nîmes, Nîmes, France.
Bonnet S; Département d'Hématologie Clinique, CHU Montpellier, Université Montpellier-Nîmes, 80, Avenue Augustin Fliche, 34090, Montpellier, France.
Tudesq JJ; Département d'Hématologie Clinique, CHU Montpellier, Université Montpellier-Nîmes, 80, Avenue Augustin Fliche, 34090, Montpellier, France.
Raffoux E; Département d'Hématologie Clinique Adultes, Hôpital Saint-Louis, APHP, Université Paris Diderot, Paris, France.
Pokaż więcej
Źródło:
Annals of hematology [Ann Hematol] 2024 Mar; Vol. 103 (3), pp. 759-769. Date of Electronic Publication: 2024 Jan 26.
Typ publikacji:
Multicenter Study; Journal Article
MeSH Terms:
Azacitidine*/adverse effects
Leukemia, Myeloid, Acute*/drug therapy
Humans ; Retrospective Studies ; Decitabine/therapeutic use ; Core Binding Factors ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Identification and in silico analysis of noval alteration Arg420Gly in KIT proto oncogene among acute myeloid leukemia patients.
Autorzy:
Akram AM; Department of Zoology, Division of Science and Technology, University of Education, Township Lahore, Pakistan. .
Hassan M; Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan.
Chaudhary A; Department of Zoology, Division of Science and Technology, University of Education, Township Lahore, Pakistan.
Hayat S; Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan.
Ali Q; Department of Plant Breeding and Genetics, Faculty of Agricultural Sciences, University of the Punjab, Lahore, Pakistan. .
Hussain T; Department of Zoology, Division of Science and Technology, University of Education, Township Lahore, Pakistan.
Zafar A; Department of Oncology, Mayo Hospital, Anarkali Bazar, Lahore, Pakistan.
Javed MA; Department of Plant Breeding and Genetics, Faculty of Agricultural Sciences, University of the Punjab, Lahore, Pakistan.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2022 Nov 10; Vol. 12 (1), pp. 19252. Date of Electronic Publication: 2022 Nov 10.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Core Binding Factors*/genetics
Leukemia, Myeloid, Acute*
Humans ; Proto-Oncogene Proteins c-kit/genetics ; Exons ; Mutation ; Prognosis ; Proto-Oncogenes
Czasopismo naukowe
Tytuł:
KIT-mutated pediatric core-binding factor systemic mastocytosis-acute myeloid leukemia treated with avapritinib and decitabine.
Autorzy:
Sheikh IN; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
AlQahtani S; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Yin CC; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
McCall D; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Cuglievan B; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ragoonanan D; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Connors JS; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Gibson A; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Nunez C; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Roth M; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ohanian M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Garcia MB; Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Pokaż więcej
Źródło:
Pediatric blood & cancer [Pediatr Blood Cancer] 2024 Apr; Vol. 71 (4), pp. e30898. Date of Electronic Publication: 2024 Jan 30.
Typ publikacji:
Letter
MeSH Terms:
Mastocytosis, Systemic*
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/genetics
Pyrazoles*
Pyrroles*
Triazines*
Humans ; Child ; Decitabine ; Core Binding Factors ; Proto-Oncogene Proteins c-kit/genetics ; Mutation
Opinia redakcyjna
Tytuł:
Clinical characteristics and prognostic factors analysis of core binding factor acute myeloid leukemia in real world.
Autorzy:
Zhai Y; Department of Hematology, Peking University First Hospital, Beijing, China.
Wang Q; Department of Hematology, Peking University First Hospital, Beijing, China.
Ji L; Department of Hematology, Peking University First Hospital, Beijing, China.
Ren H; Department of Hematology, Peking University First Hospital, Beijing, China.
Dong Y; Department of Hematology, Peking University First Hospital, Beijing, China.
Yang F; Department of Hematology, Peking University First Hospital, Beijing, China.
Yin Y; Department of Hematology, Peking University First Hospital, Beijing, China.
Liang Z; Department of Hematology, Peking University First Hospital, Beijing, China.
Wang Q; Department of Hematology, Peking University First Hospital, Beijing, China.
Liu W; Department of Hematology, Peking University First Hospital, Beijing, China.
Mei Y; Department of Hematology, Peking University First Hospital, Beijing, China.
Zhang L; Department of Hematology, Peking University First Hospital, Beijing, China.
Li Y; Department of Hematology, Peking University First Hospital, Beijing, China.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2023 Dec; Vol. 12 (24), pp. 21592-21604. Date of Electronic Publication: 2023 Dec 07.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Leukemia, Myeloid, Acute*/diagnosis
Leukemia, Myeloid, Acute*/genetics
Leukemia, Myeloid, Acute*/therapy
Hematopoietic Stem Cell Transplantation*
Adult ; Humans ; Prognosis ; Retrospective Studies ; Core Binding Factors/genetics ; Recurrence ; Risk Factors
Czasopismo naukowe
Tytuł:
Drivers of deep molecular response and long-term outcomes in patients with core binding factor acute myeloid leukemia.
Autorzy:
Patel PC; Department of Internal Medicine, University of South Florida, Tampa, Florida, USA.
Ball S; Division of Hematology and Medical Oncology, University of South Florida, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Jain AG; Division of Hematology and Medical Oncology, University of South Florida, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Wang C; Department of Internal Medicine, University of South Florida, Tampa, Florida, USA.
Hussaini MO; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Aguirre LE; Division of Hematology and Medical Oncology, University of South Florida, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Chan O; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Yun S; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Kuykendall A; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Padron E; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Sweet K; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Lancet JE; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Komrokji RS; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Sallman DA; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Pokaż więcej
Źródło:
American journal of hematology [Am J Hematol] 2023 Dec; Vol. 98 (12), pp. E360-E363. Date of Electronic Publication: 2023 Sep 13.
Typ publikacji:
Letter; Comment
MeSH Terms:
Hematopoietic Stem Cell Transplantation*/adverse effects
Leukemia, Myeloid, Acute*/therapy
Leukemia, Myeloid, Acute*/etiology
Humans ; Stem Cell Transplantation ; Core Binding Factors/genetics ; Retrospective Studies
Opinia redakcyjna
Tytuł:
The core concepts of core binding factor acute myeloid leukemia: Current considerations for prognosis and treatment.
Autorzy:
Darwish C; Tisch Cancer Institute, Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, One Gustave L Levy Place, Box 1079, New York, NY 10029, USA.
Farina K; Department of Pharmacy Practice, The Mount Sinai Hospital, New York, NY 10029, USA.
Tremblay D; Tisch Cancer Institute, Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, One Gustave L Levy Place, Box 1079, New York, NY 10029, USA. Electronic address: .
Pokaż więcej
Źródło:
Blood reviews [Blood Rev] 2023 Nov; Vol. 62, pp. 101117. Date of Electronic Publication: 2023 Jul 25.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Leukemia, Myeloid, Acute*/diagnosis
Leukemia, Myeloid, Acute*/etiology
Leukemia, Myeloid, Acute*/therapy
Humans ; Prognosis ; Cytarabine/therapeutic use ; Core Binding Factors/genetics ; Recurrence
Czasopismo naukowe
Tytuł:
Efficacy of venetoclax combined with hypomethylating agents in young, and unfit patients with newly diagnosed core binding factor acute myeloid leukemia.
Autorzy:
Zhang K; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Zhang X; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Xu Y; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.; Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China.
Xue S; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
Qiu H; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
Tang X; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.; Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China.
Han Y; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.; Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China.
Chen S; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.; Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China.
Sun A; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
Zhang Y; Department of Hematology, The Affiliated Huai'an Hospital of Xuzhou Medical University and The Second People's Hospital of Huai'an, No 62, Huaihai Road (S.), Huai'an, China. .
Wu D; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China. .; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China. .; Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China. .; State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, China. .
Wang Y; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China. .; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China. .; Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China. .
Pokaż więcej
Źródło:
Blood cancer journal [Blood Cancer J] 2023 Oct 11; Vol. 13 (1), pp. 155. Date of Electronic Publication: 2023 Oct 11.
Typ publikacji:
Letter; Research Support, Non-U.S. Gov't
MeSH Terms:
Leukemia, Myeloid, Acute*/diagnosis
Leukemia, Myeloid, Acute*/drug therapy
Humans ; Cytarabine/therapeutic use ; Bridged Bicyclo Compounds, Heterocyclic/therapeutic use ; Core Binding Factors ; Antineoplastic Combined Chemotherapy Protocols/adverse effects
Raport
Tytuł:
The Prognostic Significance of c-KIT Mutations in Core Binding Factor Acute Myeloid Leukemia.
Autorzy:
Shafik NF; Clinical Pathology and Oncologic Laboratory Medicine Department, National Cancer Institute, Cairo University, Egypt. Electronic address: .
Ibraheem D; Medical oncology Department, National Cancer Institute, Cairo University, Egypt.
Selim MM; Medical oncology Department, National Cancer Institute, Cairo University, Egypt.
Allam RM; Cancer Epidemiology and Biostatistics Department, National Cancer Institute, Cairo University, Egypt.
Fathalla LA; Clinical Pathology and Oncologic Laboratory Medicine Department, National Cancer Institute, Cairo University, Egypt.
Pokaż więcej
Źródło:
Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2022 Jun; Vol. 22 (6), pp. e363-e375. Date of Electronic Publication: 2021 Dec 02.
Typ publikacji:
Journal Article
MeSH Terms:
Core Binding Factors*/genetics
Leukemia, Myeloid, Acute*/genetics
Proto-Oncogene Proteins c-kit*/genetics
Adult ; Child ; Humans ; Mutation ; Prognosis ; Recurrence
Czasopismo naukowe
Tytuł:
CAG (cytarabine, aclarubicin and granulocyte colony-stimulating factor) regimen for core binding factor acute myeloid leukaemia with measurable residual disease.
Autorzy:
Shen YJ; Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.; Department of Haematology, the First Affiliated Hospital, Zhejiang University School of Medicine, No.79 Qingchun Road, 310003, Hangzhou, Zhejiang Province, People's Republic of China.
Zhang Y; Department of Haematology, the First Affiliated Hospital, Zhejiang University School of Medicine, No.79 Qingchun Road, 310003, Hangzhou, Zhejiang Province, People's Republic of China.; Zhejiang Provincial Clinical Research Center for Haematological Disorders, Hangzhou, People's Republic of China.
Chang J; Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.; Department of Haematology, the First Affiliated Hospital, Zhejiang University School of Medicine, No.79 Qingchun Road, 310003, Hangzhou, Zhejiang Province, People's Republic of China.
Wang HF; Department of Haematology, the First Affiliated Hospital, Zhejiang University School of Medicine, No.79 Qingchun Road, 310003, Hangzhou, Zhejiang Province, People's Republic of China.; Zhejiang Provincial Clinical Research Center for Haematological Disorders, Hangzhou, People's Republic of China.
Ye XN; Department of Haematology, the First Affiliated Hospital, Zhejiang University School of Medicine, No.79 Qingchun Road, 310003, Hangzhou, Zhejiang Province, People's Republic of China.; Zhejiang Provincial Clinical Research Center for Haematological Disorders, Hangzhou, People's Republic of China.
Zhu L; Department of Haematology, the First Affiliated Hospital, Zhejiang University School of Medicine, No.79 Qingchun Road, 310003, Hangzhou, Zhejiang Province, People's Republic of China.; Zhejiang Provincial Clinical Research Center for Haematological Disorders, Hangzhou, People's Republic of China.
Jin J; Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.; Department of Haematology, the First Affiliated Hospital, Zhejiang University School of Medicine, No.79 Qingchun Road, 310003, Hangzhou, Zhejiang Province, People's Republic of China.; Zhejiang Provincial Clinical Research Center for Haematological Disorders, Hangzhou, People's Republic of China.
Zhu HH; Zhejiang Provincial Key Laboratory of Hematopoietic Malignancy, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China. .; Department of Haematology, the First Affiliated Hospital, Zhejiang University School of Medicine, No.79 Qingchun Road, 310003, Hangzhou, Zhejiang Province, People's Republic of China. .; Zhejiang Provincial Clinical Research Center for Haematological Disorders, Hangzhou, People's Republic of China. .
Pokaż więcej
Źródło:
Annals of hematology [Ann Hematol] 2023 Jul; Vol. 102 (7), pp. 1731-1738. Date of Electronic Publication: 2023 May 05.
Typ publikacji:
Journal Article
MeSH Terms:
Leukemia, Myeloid, Acute*/drug therapy
Neutropenia*/chemically induced
Humans ; Aclarubicin ; Retrospective Studies ; Treatment Outcome ; Neoplasm Recurrence, Local/drug therapy ; Cytarabine ; Granulocyte Colony-Stimulating Factor/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Core Binding Factors
Czasopismo naukowe
Tytuł:
Clinical impact of c-KIT and CEBPA mutations in 33 patients with corebinding factor (Non-M3) acute myeloid leukemia.
Autorzy:
Mao X; Department of Pediatrics, Children Hematological Oncology and Birth Defects Laboratory, The Affiliated Hospital of Southwest Medical University, Sichuan Clinical Research Center for Birth Defects, Luzhou, Sichuan 646000, China; Kunming Medical University, Kunming City, Yunnan province, China.
Yin R; Department of Hematology, Kunming Children's Hospital (The Affiliated Children's Hospital of Kunming Medical University, Yunnan Key Laboratory of Children's Major Disease Research), Kunming Medical University, Kunming City, Yunnan province, China.
Liu L; Kunming Medical University, Kunming City, Yunnan province, China.
Zhou Y; Department of Hematology, Kunming Children's Hospital (The Affiliated Children's Hospital of Kunming Medical University, Yunnan Key Laboratory of Children's Major Disease Research), Kunming Medical University, Kunming City, Yunnan province, China.
Yang C; Department of Hematology, Kunming Children's Hospital (The Affiliated Children's Hospital of Kunming Medical University, Yunnan Key Laboratory of Children's Major Disease Research), Kunming Medical University, Kunming City, Yunnan province, China.
Fang C; Department of Hematology, Kunming Children's Hospital (The Affiliated Children's Hospital of Kunming Medical University, Yunnan Key Laboratory of Children's Major Disease Research), Kunming Medical University, Kunming City, Yunnan province, China.
Jiang H; Department of Hematology, Kunming Children's Hospital (The Affiliated Children's Hospital of Kunming Medical University, Yunnan Key Laboratory of Children's Major Disease Research), Kunming Medical University, Kunming City, Yunnan province, China.
Guo Q; Department of Pediatrics, Children Hematological Oncology and Birth Defects Laboratory, The Affiliated Hospital of Southwest Medical University, Sichuan Clinical Research Center for Birth Defects, Luzhou, Sichuan 646000, China.
Tian X; Department of Hematology, Kunming Children's Hospital (The Affiliated Children's Hospital of Kunming Medical University, Yunnan Key Laboratory of Children's Major Disease Research), Kunming Medical University, Kunming City, Yunnan province, China. Electronic address: .
Pokaż więcej
Źródło:
Pediatrics and neonatology [Pediatr Neonatol] 2023 Jul; Vol. 64 (4), pp. 435-441. Date of Electronic Publication: 2023 Jan 26.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Leukemia, Myeloid, Acute*/epidemiology
Leukemia, Myeloid, Acute*/genetics
Humans ; Retrospective Studies ; Core Binding Factors/genetics ; Male ; Female ; Child ; China/epidemiology
Czasopismo naukowe
Tytuł:
Prognostic of Core Binding Factor (CBF) Acute Myeloid Leukemia With Complex Karyotype.
Autorzy:
Marcault C; CHU of Nice, Hematology department, Cote D'Azur University, Nice Sophia Antipolis University, Nice, France.
Boissel N; Saint-Louis Hospital, Hematology Department, Institut de Recherche Saint-Louis, Paris University, Paris, France.
Haferlach C; MLL Munich Leukemia Laboratory, Munich, Germany.
Loschi M; CHU of Nice, Hematology department, Cote D'Azur University, Nice Sophia Antipolis University, Nice, France; INSERM U1065, Mediterranean Center of Molecular Medecine, Cote D'Azur University, Nice, France.
Raynaud S; CHU of Nice, Onco-hematology Laboratory, Cote D'Azur University, Nice Sophia Antipolis University, Nice, France.
Cluzeau T; CHU of Nice, Hematology department, Cote D'Azur University, Nice Sophia Antipolis University, Nice, France; INSERM U1065, Mediterranean Center of Molecular Medecine, Cote D'Azur University, Nice, France. Electronic address: .
Pokaż więcej
Źródło:
Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2022 Mar; Vol. 22 (3), pp. e199-e205. Date of Electronic Publication: 2021 Sep 11.
Typ publikacji:
Journal Article
MeSH Terms:
Core Binding Factors*/genetics
Leukemia, Myeloid, Acute*/diagnosis
Leukemia, Myeloid, Acute*/genetics
Leukemia, Myeloid, Acute*/therapy
Abnormal Karyotype ; Humans ; Karyotyping ; Middle Aged ; Prognosis
Czasopismo naukowe
Tytuł:
Core binding factor acute myelogenous leukemia-2021 treatment algorithm.
Autorzy:
Borthakur G; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA. .
Kantarjian H; Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.
Pokaż więcej
Źródło:
Blood cancer journal [Blood Cancer J] 2021 Jun 16; Vol. 11 (6), pp. 114. Date of Electronic Publication: 2021 Jun 16.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Algorithms*
Core Binding Factors*/blood
Core Binding Factors*/genetics
Leukemia, Myeloid, Acute*/blood
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/genetics
Neoplasm Proteins*/blood
Neoplasm Proteins*/genetics
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Anthracyclines/therapeutic use ; Chromosome Inversion ; Chromosomes, Human/genetics ; Chromosomes, Human/metabolism ; Cytarabine/therapeutic use ; Disease-Free Survival ; Humans ; Neoplasm, Residual ; Translocation, Genetic
Czasopismo naukowe
Tytuł:
Autologous hematopoietic cell transplantation following high-dose cytarabine consolidation for core-binding factor-acute myeloid leukemia in first complete remission: a phase 2 prospective trial.
Autorzy:
Choi EJ; Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea.
Lee JH; Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea. .
Kim H; Division of Hematology, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.
Choi Y; Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
Lee WS; Department of Hematology and Oncology, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.
Lee SM; Department of Hematology and Oncology, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.
Park JH; Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea.
Park HS; Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea.
Lee JH; Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea.
Lee KH; Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea.
Pokaż więcej
Corporate Authors:
CoOperative Study Group A for Hematology (COSAH)
Źródło:
International journal of hematology [Int J Hematol] 2021 Jun; Vol. 113 (6), pp. 851-860. Date of Electronic Publication: 2021 Mar 02.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Multicenter Study
MeSH Terms:
Consolidation Chemotherapy*
Core Binding Factors*/genetics
Core Binding Factors*/metabolism
Hematopoietic Stem Cell Transplantation*
Leukemia, Myeloid, Acute*/genetics
Leukemia, Myeloid, Acute*/metabolism
Leukemia, Myeloid, Acute*/mortality
Leukemia, Myeloid, Acute*/therapy
Neoplasm Proteins*/genetics
Neoplasm Proteins*/metabolism
Cytarabine/*administration & dosage
Adult ; Autografts ; Chromosome Aberrations ; Chromosomes, Human/genetics ; Chromosomes, Human/metabolism ; Disease-Free Survival ; Female ; Humans ; Male ; Middle Aged ; Remission Induction ; Survival Rate
Czasopismo naukowe
Tytuł:
Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens.
Autorzy:
Senapati J; Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
Abuasab T; Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
Haddad FG; Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
Ravandi F; Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
Kadia T; Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
DiNardo C; Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
Daver N; Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
Pemmaraju N; Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
Alvarado Y; Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
Brandt MA; Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
Kantarjian H; Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
Borthakur G; Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
Pokaż więcej
Źródło:
American journal of hematology [Am J Hematol] 2023 Mar; Vol. 98 (3), pp. E53-E56. Date of Electronic Publication: 2022 Dec 24.
Typ publikacji:
Letter
MeSH Terms:
Cytarabine*/therapeutic use
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/genetics
Humans ; Granulocyte Colony-Stimulating Factor/therapeutic use ; Vidarabine/therapeutic use ; Mutation ; Core Binding Factors ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Opinia redakcyjna
Tytuł:
Comparison of therapy-related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study.
Autorzy:
Rogers HJ; Department of Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
Wang X; Department of Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
Xie Y; Department of Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
Davis AR; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Thakral B; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Wang SA; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Borthakur G; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Cantu MD; Department of Pathology, Weill Cornell Medicine, New York, New York, USA.
Margolskee EM; Department of Pathology, Weill Cornell Medicine, New York, New York, USA.
Philip JKS; Department of Pathology, University of Chicago, Chicago, Illinois, USA.
Sukhanova M; Department of Pathology, Northwestern University, Chicago, Illinois, USA.
Bagg A; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Bueso-Ramos CE; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Orazi A; Department of Pathology, Texas Tech University Health Science Center, El Paso, Texas, USA.
Arber DA; Department of Pathology, University of Chicago, Chicago, Illinois, USA.
Hsi ED; Department of Laboratory Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
Hasserjian RP; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Pokaż więcej
Źródło:
American journal of hematology [Am J Hematol] 2020 Jul; Vol. 95 (7), pp. 799-808. Date of Electronic Publication: 2020 Apr 20.
Typ publikacji:
Clinical Trial; Comparative Study; Journal Article; Multicenter Study
MeSH Terms:
Chromosome Aberrations*
Core Binding Factors*/genetics
Core Binding Factors*/metabolism
Leukemia, Myeloid, Acute*/genetics
Leukemia, Myeloid, Acute*/metabolism
Leukemia, Myeloid, Acute*/mortality
Leukemia, Myeloid, Acute*/therapy
Neoplasm Proteins*/genetics
Neoplasm Proteins*/metabolism
Adult ; Disease-Free Survival ; Female ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Survival Rate
Czasopismo naukowe
Tytuł:
Wood Architecture and Composition Are Deeply Remodeled in Frost Sensitive Eucalyptus Overexpressing CBF/DREB1 Transcription Factors.
Autorzy:
Cao PB; Laboratoire de Recherche en Sciences Végétales, Université de Toulouse III, CNRS, UPS, UMR 5546, 31320 Castanet-Tolosan, France.; Department of Natural Sciences, Hung Vuong University, Nong Trang Ward, Viet Tri City, Phu Tho Province 29000, Vietnam.
Ployet R; Laboratoire de Recherche en Sciences Végétales, Université de Toulouse III, CNRS, UPS, UMR 5546, 31320 Castanet-Tolosan, France.; Department of Biochemistry, Genetics and Microbiology, Forestry and Agricultural Biotechnology Institute (FABI), University of Pretoria, Pretoria 0002, South Africa.
Nguyen C; Laboratoire de Recherche en Sciences Végétales, Université de Toulouse III, CNRS, UPS, UMR 5546, 31320 Castanet-Tolosan, France.; Biotechnology and crop protection Department; Northern Mountainous Agriculture and Forestry Science Institute, Phu Tho 29000, Vietnam.
Dupas A; Laboratoire de Recherche en Sciences Végétales, Université de Toulouse III, CNRS, UPS, UMR 5546, 31320 Castanet-Tolosan, France.
Ladouce N; Laboratoire de Recherche en Sciences Végétales, Université de Toulouse III, CNRS, UPS, UMR 5546, 31320 Castanet-Tolosan, France.
Martinez Y; CMEAB, IFR40 Pôle de Biotechnologie Végétale, 31320 Castanet-Tolosan, France.
Grima-Pettenati J; Laboratoire de Recherche en Sciences Végétales, Université de Toulouse III, CNRS, UPS, UMR 5546, 31320 Castanet-Tolosan, France.
Marque C; Laboratoire de Recherche en Sciences Végétales, Université de Toulouse III, CNRS, UPS, UMR 5546, 31320 Castanet-Tolosan, France.
Mounet F; Laboratoire de Recherche en Sciences Végétales, Université de Toulouse III, CNRS, UPS, UMR 5546, 31320 Castanet-Tolosan, France.
Teulières C; Laboratoire de Recherche en Sciences Végétales, Université de Toulouse III, CNRS, UPS, UMR 5546, 31320 Castanet-Tolosan, France.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2020 Apr 24; Vol. 21 (8). Date of Electronic Publication: 2020 Apr 24.
Typ publikacji:
Journal Article
MeSH Terms:
Cold-Shock Response*
Gene Expression*
Core Binding Factors/*genetics
Eucalyptus/*genetics
Transcription Factors/*genetics
Wood/*anatomy & histology
Wood/*genetics
Core Binding Factors/metabolism ; Gene Expression Regulation, Plant ; Genes, Plant ; Lignin/metabolism ; Phenotype ; Plants, Genetically Modified ; Transcription Factors/metabolism ; Wood/chemistry ; Xylem/genetics ; Xylem/metabolism
Czasopismo naukowe
Tytuł:
Different prognostic effects of core-binding factor positive AML with Korean AML registry data.
Autorzy:
Shin HJ; Division of Hematology-Oncology, Department of Internal Medicine, School of Medicine, Medical Research Institute, Pusan National University Hospital, Busan, South Korea.
Min WS; Division of Hematology, Department of Internal Medicine, Catholic Hematology Hospital, Seoul St. Mary's Hospital, Leukemia Research Institute, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, Republic of Korea.
Min YH; Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.
Cheong JW; Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.
Lee JH; Department of Hematology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Kim IH; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
Hong DS; Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University, Bucheon, South Korea.
Ahn JS; Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Jeollanam-do, South Korea.
Kim HJ; Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Jeollanam-do, South Korea.
Lee WS; Department of Internal Medicine, Inje University Busan Paik Hospital, Busan, South Korea.
Jung CW; Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Jang JH; Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Park Y; Division of Oncology and Hematology, Department of Internal Medicine, Korea University Medical Center, Seoul, South Korea.
Kim HJ; Division of Hematology, Department of Internal Medicine, Catholic Hematology Hospital, Seoul St. Mary's Hospital, Leukemia Research Institute, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, Republic of Korea. .
Pokaż więcej
Corporate Authors:
Korean Society of Hematology AML/MDS Working Party
Źródło:
Annals of hematology [Ann Hematol] 2019 May; Vol. 98 (5), pp. 1135-1147. Date of Electronic Publication: 2019 Feb 13.
Typ publikacji:
Journal Article
MeSH Terms:
Chromosomes, Human*/genetics
Chromosomes, Human*/metabolism
Core Binding Factors*/genetics
Core Binding Factors*/metabolism
Leukemia, Myeloid, Acute*/genetics
Leukemia, Myeloid, Acute*/metabolism
Leukemia, Myeloid, Acute*/mortality
Registries*
Translocation, Genetic*
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Disease-Free Survival ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Proteins ; Republic of Korea/epidemiology ; Survival Rate
Czasopismo naukowe
Tytuł:
A 5-microRNA signature derived from core binding factor-AML is predictive in adult and childhood AML.
Autorzy:
Gabra MM; Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada.
Chow JT; Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada.
Kim T; Department of Computer Science, University of Toronto, Toronto, Ontario, Canada.
Son MH; Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Arruda A; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Woolley JF; Department of Pharmacology & Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, UK.
Zhang Z; Department of Computer Science, University of Toronto, Toronto, Ontario, Canada; The Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, Ontario, Canada; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
Minden MD; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
Salmena L; Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. Electronic address: .
Pokaż więcej
Źródło:
Leukemia research [Leuk Res] 2022 Dec; Vol. 123, pp. 106968. Date of Electronic Publication: 2022 Oct 08.
Typ publikacji:
Letter; Research Support, Non-U.S. Gov't
MeSH Terms:
MicroRNAs*/genetics
Leukemia, Myeloid, Acute*/genetics
Adult ; Child ; Humans ; Core Binding Factors ; Prognosis
Raport
Tytuł:
Regulome analysis in B-acute lymphoblastic leukemia exposes Core Binding Factor addiction as a therapeutic vulnerability.
Autorzy:
Wray JP; Department of Cancer Biology UCL Cancer Institute, UCL, London, WC1E 6DD, UK.
Deltcheva EM; Department of Cancer Biology UCL Cancer Institute, UCL, London, WC1E 6DD, UK.
Boiers C; Department of Cancer Biology UCL Cancer Institute, UCL, London, WC1E 6DD, UK.; Division of Molecular Hematology, Lund Stem Cell Center, Lund University, 221 84, Lund, Sweden.
Richardson SЕ; Department of Cancer Biology UCL Cancer Institute, UCL, London, WC1E 6DD, UK.; Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, CB2 0AW, UK.; Department of Haematology, University of Cambridge, Jeffrey Cheah Biomedical Centre, Cambridge, CB2 0AW, UK.
Chhetri JB; Department of Cancer Biology UCL Cancer Institute, UCL, London, WC1E 6DD, UK.
Brown J; Department of Cancer Biology UCL Cancer Institute, UCL, London, WC1E 6DD, UK.
Gagrica S; IMED Oncology, AstraZeneca, Cancer Research UK Cambridge Institute, Cambridge, UK.
Guo Y; Department of Cancer Biology UCL Cancer Institute, UCL, London, WC1E 6DD, UK.
Illendula A; Department of Pharmacology, University of Virginia, Charlottesville, VA, 22908, USA.
Martens JHA; Department of Molecular Biology, Faculty of Science, Radboud Institute for Molecular Life Sciences, Radboud University, 6525, GA, Nijmegen, The Netherlands.
Stunnenberg HG; Department of Molecular Biology, Faculty of Science, Radboud Institute for Molecular Life Sciences, Radboud University, 6525, GA, Nijmegen, The Netherlands.
Bushweller JH; Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, VA, 22908, USA.
Nimmo R; Department of Cancer Biology UCL Cancer Institute, UCL, London, WC1E 6DD, UK.; Oxford Biomedica (UK) Ltd, Windrush Court, Transport Way, Oxford, OX4 6LT, UK.
Enver T; Department of Cancer Biology UCL Cancer Institute, UCL, London, WC1E 6DD, UK. .; Division of Molecular Hematology, Lund Stem Cell Center, Lund University, 221 84, Lund, Sweden. .; Molecular Medicine and Gene Therapy, Lund Stem Cell Center, Lund University, Lund, Sweden. .
Pokaż więcej
Źródło:
Nature communications [Nat Commun] 2022 Nov 21; Vol. 13 (1), pp. 7124. Date of Electronic Publication: 2022 Nov 21.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Core Binding Factor Alpha 2 Subunit*/genetics
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/genetics
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/therapy
Adult ; Child ; Humans ; Core Binding Factors ; B-Lymphocytes ; Gene Fusion
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies